Skip to main navigation Skip to main content

Clin Mol Hepatol : Clinical and Molecular Hepatology

OPEN ACCESS
ABOUT
BROWSE ARTICLES
FOR CONTRIBUTORS

Page Path

2
results for

"Seung Min Jung"

Article category

Keywords

Publication year

"Seung Min Jung"

Original Article

Hepatic neoplasm

Preemptive antiviral therapy with entecavir can reduce acute deterioration of hepatic function following transarterial chemoembolization
Sun Hong Yoo, Jeong Won Jang, Jung Hyun Kwon, Seung Min Jung, Bohyun Jang, Jong Young Choi
Clin Mol Hepatol 2016;22(4):458-465.
Published online December 25, 2016
DOI: https://doi.org/10.3350/cmh.2016.0054
Background/Aims
Hepatic damage during transarterial chemoembolization (TACE) is a critical complication in patients with hepatitis B virus (HBV)-related hepatocellular carcinoma (HCC). Apart from its role in preventing HBV reactivation, there is some evidence for the benefits of preemptive antiviral therapy in TACE. This study evaluated the effect of preemptive antiviral therapy on acute hepatic deterioration following TACE.
Methods
This retrospective observational study included a prospectively collected cohort of 108 patients with HBV-related HCC who underwent TACE between January 2007 and January 2013. Acute hepatic deterioration following TACE was evaluated. Treatment-related hepatic decompensation was defined as newly developed encephalopathy, ascites, variceal bleeding, elevation of the bilirubin level, prolongation of prothrombin time, or elevation of the Child-Pugh score by ≥2 within 2 weeks following TACE. Univariate and multivariate analyses were conducted to identify factors influencing treatment-related decompensation. Preemptive antiviral therapy involves directing prophylaxis only toward high-risk chronic hepatitis B patients in an attempt to prevent the progression of liver disease. We regarded at least 6 months as a significant duration of preemptive antiviral treatment before diagnosis of HCC.
Results
Of the 108 patients, 30 (27.8%) patients received preemptive antiviral therapy. Treatment-related decompensation was observed in 25 (23.1%) patients during the follow-up period. Treatment-related decompensation following TACE was observed more frequently in the nonpreemptive group than in the preemptive group (29.5% vs. 6.7%, P=0.008). In the multivariate analysis, higher serum total bilirubin (Hazard ratio [HR] =3.425, P=0.013), hypoalbuminemia (HR=3.990, P=0.015), and absence of antiviral therapy (HR=7.597, P=0.006) were significantly associated with treatment-related hepatic decompensation.
Conclusions
Our findings suggest that preemptive antiviral therapy significantly reduces the risk of acute hepatic deterioration. Preventing hepatic deterioration during TACE by applying such a preemptive approach may facilitate the continuation of anticancer therapy and thus improve long-term outcomes.

Citations

Citations to this article as recorded by  Crossref logo
  • Microbial metabolism dysfunction induced by transarterial chemoembolization aggravates postprocedural liver injury in HCC
    Rui Li, Jianxin Liu, Feilong Ye, Siqin He, Jingjun Huang, Mengdan Zhou, Qifeng Xie, Zhile Liu, Wei Cheng, Guodong Wang, Wei Deng, Xiaobin Wang, Tingqi Yang, Zhengyang Liang, Feiyan Hu, Wensou Huang, Mingyue Cai, Lulu Xie, Wen Zhang, Shenhai Gong, Yun Chen
    Journal of Hepatology.2026; 84(4): 808.     CrossRef
  • Precore/core mutation relatedness to viral reactivation in patients undergoing targeted therapy for hepatitis B virus-related hepatocellular carcinoma
    Mohammed S Abdulrahman, Omnia Aboelmagd, Ying Zhang, Samy Zaky, Dina Johar
    World Journal of Biological Chemistry.2026;[Epub]     CrossRef
  • KASL clinical practice guidelines for management of chronic hepatitis B Endorsed by the East Asia Liver Alliance (EALA)
    Won-Mook Choi, Ji Won Han, Tae Hyung Kim, Miyoung Choi, Moon Haeng Hur, Hyo Young Lee, Han Ah Lee, Byeong Geun Song, Heechul Nam, Jeong-Ju Yoo, Chang Hun Lee, Gi-Ae Kim, Hye Won Lee, Gwang Hyeon Choi, Young Eun Chon, Yun Bin Lee, Dong Hyun Sinn, Bo Hyun K
    Clinical and Molecular Hepatology.2026; 32(3): 1029.     CrossRef
  • Impact of frailty on the long-term prognosis of the elderly with hepatocellular carcinoma treated with transarterial chemoembolization
    Yu-Fei Shao, Ya-Nan Zu, Xiang-Qi Yin, Jin-Chang Xiao, Yu-Ming Gu
    Scientific Reports.2025;[Epub]     CrossRef
  • EASL Clinical Practice Guidelines on the management of hepatitis B virus infection
    Markus Cornberg, Lisa Sandmann, Jerzy Jaroszewicz, Patrick Kennedy, Pietro Lampertico, Maud Lemoine, Sabela Lens, Barbara Testoni, Grace Lai-Hung Wong, Francesco Paolo Russo
    Journal of Hepatology.2025; 83(2): 502.     CrossRef
  • 5-FU promotes HBV replication through oxidative stress-induced autophagy dysfunction
    Jing Yang, Luyan Zheng, Zhenggang Yang, Zhiqiang Wei, Jiajia Shao, Yina Zhang, Jiping Yao, Minwei Li, Xueyu Wang, Min Zheng
    Free Radical Biology and Medicine.2024; 213: 233.     CrossRef
  • Liver Injury and Its Impact on Prognosis in Patients with HBV-Related Hepatocellular Carcinoma Undergoing Transarterial Chemoembolization Combined with Tyrosine Kinase Inhibitors Plus Immune Checkpoint Inhibitors
    Jiaming Shen, Xia Wang, Guangde Yang, Li Li, Juanjuan Fu, Wei Xu, Qingqiao Zhang, Xiucheng Pan
    Journal of Hepatocellular Carcinoma.2024; Volume 11: 207.     CrossRef
  • Sorafenib plus transcatheter arterial chemoembolization with or without camrelizumab for the treatment of intermediate and advanced hepatocellular carcinoma
    Bo Sun, Lei Chen, Yu Lei, Lijie Zhang, Tao Sun, Yiming Liu, Chuansheng Zheng
    British Journal of Radiology.2024; 97(1159): 1320.     CrossRef
  • TACE versus TACE + entecavir versus TACE + tenofovir in the treatment of HBV associated hepatocellular carcinoma
    Haohao Lu, Chuansheng Zheng, Bin Xiong, Xiangwen Xia
    BMC Cancer.2023;[Epub]     CrossRef
  • S3-Leitlinie der Deutschen Gesellschaft für Gastroenterologie, Verdauungs- und Stoffwechselkrankheiten (DGVS) zur Prophylaxe, Diagnostik und Therapie der Hepatitis-B-Virusinfektion – (AWMF-Register-Nr. 021-11)
    Markus Cornberg, Lisa Sandmann, Ulrike Protzer, Claus Niederau, Frank Tacke, Thomas Berg, Dieter Glebe, Wolfgang Jilg, Heiner Wedemeyer, Stefan Wirth, Christoph Höner zu Siederdissen, Petra Lynen-Jansen, Pia van Leeuwen, Jörg Petersen
    Zeitschrift für Gastroenterologie.2021; 59(07): 691.     CrossRef
  • Association of Prophylactic Anti–Hepatitis B Virus Therapy With Improved Long-term Survival in Patients With Hepatocellular Carcinoma Undergoing Transarterial Therapy
    Jeong Won Jang, Sun Hong Yoo, Hee Chul Nam, Bo Hyun Jang, Pil Soo Sung, Sung, Won Lee, Jung Hyun Kwon, Soon Woo Nam, Si Hyun Bae, Seung Kew Yoon, Jong Young Choi
    Clinical Infectious Diseases.2020; 71(3): 546.     CrossRef
  • Nucleos(t)ide analogues and Hepatitis B virus-related hepatocellular carcinoma: A literature review
    Mohamed A Abd El Aziz, Rodolfo Sacco, Antonio Facciorusso
    Antiviral Chemistry and Chemotherapy.2020; 28: 204020662092133.     CrossRef
  • Efficacy of microwave ablation and entecavir as a combination treatment for primary liver cancer and their effects on hepatitis B virus and liver function
    Hong Xu, Qiang Zhang, Yu-Lin Tan, Yang Zhang, Jian-Zhu Wei, Ling-Ling Wang, Bo Xie
    All Life.2020; 13(1): 524.     CrossRef
  • Effects of TACE and preventive antiviral therapy on HBV reactivation and subsequent hepatitis in hepatocellular carcinoma: a meta-analysis
    Su-Su Zhang, Jin-Xia Liu, Jing Zhu, Ming-Bing Xiao, Cui-Hua Lu, Run-Zhou Ni, Li-Shuai Qu
    Japanese Journal of Clinical Oncology.2019; 49(7): 646.     CrossRef
  • Hepatitis B virus reactivation after radiotherapy for hepatocellular carcinoma and efficacy of antiviral treatment: A multicenter study
    Baek Gyu Jun, Young Don Kim, Sang Gyune Kim, Young Seok Kim, Soung Won Jeong, Jae Young Jang, Sae Hwan Lee, Hong Soo Kim, Seong Hee Kang, Moon Young Kim, Soon Koo Baik, Minjong Lee, Tae-Suk Kim, Dae Hee Choi, Sang-Hyeon Choi, Ki Tae Suk, Dong Joon Kim, Ga
    PLOS ONE.2018; 13(7): e0201316.     CrossRef
  • 13,685 View
  • 146 Download
  • 13 Web of Science
  • Crossref
Case Report

Steatotic liver disease

Severe steatohepatitis with hepatic decompensation resulting from malnutrition after pancreaticoduodenectomy
Eun Hui Sim, Jung Hyun Kwon, Se Young Kim, Seung Min Jung, Lee-So Maeng, Jeong Won Jang, Kyu Won Chung
Korean J Hepatol 2012;18(4):404-410.
Published online December 21, 2012
DOI: https://doi.org/10.3350/cmh.2012.18.4.404

The most common finding related to nonalcoholic steatohepatitis is obesity, but a status of severe malnutrition can also induce the steatohepatitis. The authors report a rare case of steatohepatitis leading to hepatic decompensation caused by malnutrition after pancreaticoduodenectomy. A 68-year-old female patient who had been previously diagnosed with pancreatic cancer and had undergone pancreaticoduodenectomy 5 months previously presented with abdominal distension. Routine CT performed 3 months after the surgery revealed severe fatty liver without evidence of tumor recurrence. After undergoing pancreaticoduodenectomy her food intake had reduced, and as a result she had lost 7 kg of body weight over 2 months. At this admission, CT revealed moderate amounts of ascites without tumor recurrence. Furthermore, her albumin and lipid profile levels were markedly decreased, and she had a flapping tremor and slurred speech suggestive of hepatic encephalopathy. Her liver biopsy findings were consistent with steatohepatitis and disclosed macrovesicular steatosis without definite fibrosis. After careful nutritional control, her symptoms disappeared and her laboratory findings improved.

Citations

Citations to this article as recorded by  Crossref logo
  • Rapid progression to liver failure following pancreatoduodenectomy in an adolescent: A case report
    Han Hu, Yu-Juan Liu, Mei-Chuan Li, Yan Li, Shi-De Lin
    World Journal of Gastroenterology.2026;[Epub]     CrossRef
  • Cirrhosis after pancreaticoduodenectomy for pancreatic cancer
    Rui Su, Hong-Na Liu, Yu-Bo Wang, Yun Bai
    Hepatobiliary & Pancreatic Diseases International.2025; 24(2): 232.     CrossRef
  • Liver Transplantation for Metabolic Dysfunction-Associated Steatotic Liver Disease after Pancreaticoduodenectomy
    Takeshi Kano, Ryugen Takahashi, Nobuhisa Akamatsu, Yujiro Nishioka, Yuichiro Mihara, Akihiko Ichida, Takeshi Takamoto, Yoshikuni Kawaguchi, Kiyoshi Hasegawa
    Surgical Case Reports.2025; 11(1): n/a.     CrossRef
  • Are transmembrane 6 superfamily member 2 gene polymorphisms associated with steatohepatitis after pancreaticoduodenectomy?
    Tomotaka Mori, Eisuke Ozawa, Ryu Sasaki, Akane Shimakura, Kosuke Takahashi, Yoko Kido, Yasuko Kanda, Satoshi Matsuo, Kazuaki Tajima, Asami Beppu, Yasuhiko Nakao, Masanori Fukushima, Masafumi Haraguchi, Satoshi Miuma, Hisamitsu Miyaaki, Tomohiko Adachi, Su
    JGH Open.2024;[Epub]     CrossRef
  • Review article: Hepatic steatosis and its associations with acute and chronic liver diseases
    Aaron B. Koenig, Albert Tan, Hala Abdelaal, Fanny Monge, Zobair M. Younossi, Zachary D. Goodman
    Alimentary Pharmacology & Therapeutics.2024; 60(2): 167.     CrossRef
  • Prevalence of metabolic dysfunction-associated fatty liver disease after pancreatic surgery in a historical Belgian cohort and review of the literature
    V D’Cruz, A De Zutter, M Van den Broecke, S Ribeiro, L Abreu de Carvalho, P Smeets, C Lecluyse, E Pape, E Callebout, F Berrevoet, K Geboes
    Acta Gastro Enterologica Belgica.2024; 87(3): 373.     CrossRef
  • Hepatic Steatosis After Partial Pancreatectomy in a Cohort of Patients with Intraductal Papillary Mucinous Neoplasm
    Zhenteng Li, Jonathan Weinstein, Ellen Redstone, Donald G. Mitchell
    Journal of Clinical and Experimental Hepatology.2023; 13(6): 955.     CrossRef
  • Association Between Neoadjuvant Chemoradiotherapy and Intractable Serous Ascites After Pancreaticoduodenectomy for Pancreatic Cancer
    Atsushi Tomioka, Tetsunosuke Shimizu, Shuji Kagota, Kohei Taniguchi, Koji Komeda, Mitsuhiro Asakuma, Fumitoshi Hirokawa, Kazuhisa Uchiyama
    Annals of Surgical Oncology.2021; 28(7): 3789.     CrossRef
  • Nonalcoholic Fatty Liver Disease After Pancreaticoduodenectomy for a Cancer Diagnosis
    Amy E. McGhee-Jez, Inna Chervoneva, Misung Yi, Amisha Ahuja, Ritu Nahar, Samik Shah, Rebecca Loh, Sarah Houtmann, Rashesh Shah, Charles J. Yeo, Harish Lavu, Steven J. Cohen, Dina Halegoua-DeMarzio, Atrayee Basu Mallick
    Journal of Pancreatic Cancer.2021; 7(1): 23.     CrossRef
  • Preventive Effect of High-Dose Digestive Enzyme Management on Development of Nonalcoholic Fatty Liver Disease after Pancreaticoduodenectomy: A Randomized Controlled Clinical Trial
    Koya Yasukawa, Akira Shimizu, Takahide Yokoyama, Koji Kubota, Tsuyoshi Notake, Hitoshi Seki, Akira Kobayashi, Yuji Soejima
    Journal of the American College of Surgeons.2020; 231(6): 658.     CrossRef
  • New onset non‐alcoholic fatty liver disease after resection of pancreatic neuroendocrine tumors
    Tara Michella Mackay, Cansu Güney Genç, Robert Bart Takkenberg, Marc Gerard Besselink, Inne Somers, Elisabeth Jacqueline Maria Nieveen van Dijkum
    Journal of Surgical Oncology.2018; 117(7): 1548.     CrossRef
  • Risk Factors for and Management of Postpancreatectomy Hepatic Steatosis
    N. Takemura, A. Saiura, R. Koga, J. Yamamoto, T. Yamaguchi
    Scandinavian Journal of Surgery.2017; 106(3): 224.     CrossRef
  • Risk factors for development of nonalcoholic fatty liver disease after pancreatoduodenectomy
    Yoshiro Fujii, Atsushi Nanashima, Masahide Hiyoshi, Naoya Imamura, Koichi Yano, Takeomi Hamada
    Annals of Gastroenterological Surgery.2017; 1(3): 226.     CrossRef
  • Clinical Characteristics and Risk Factors for the Development of Postoperative Hepatic Steatosis After Total Pancreatectomy
    Tatsuo Hata, Masaharu Ishida, Fuyuhiko Motoi, Naoaki Sakata, Gumpei Yoshimatsu, Takeshi Naitoh, Yu Katayose, Shinichi Egawa, Michiaki Unno
    Pancreas.2016; 45(3): 362.     CrossRef
  • Pathophysiology after pancreaticoduodenectomy
    Chang Moo Kang, Jin Ho Lee
    World Journal of Gastroenterology.2015; 21(19): 5794.     CrossRef
  • Nonalcoholic fatty liver disease after pancreatoduodenectomy is closely associated with postoperative pancreatic exocrine insufficiency
    Naoya Nakagawa, Yoshiaki Murakami, Kenichiro Uemura, Takeshi Sudo, Yasushi Hashimoto, Naru Kondo, Hayato Sasaki, Keisuke Okano, Taijiro Sueda
    Journal of Surgical Oncology.2014; 110(6): 720.     CrossRef
  • Prevalence Analysis of de novo Hepatic Steatosis Following Pylorus-Preserving Pancreaticoduodenectomy
    Dae-Gwang Yoo, Bo-Hyun Jung, Shin Hwang, Song-Chul Kim, Ki-Hun Kim, Young-Joo Lee, Chul-Soo Ahn, Deok-Bog Moon, Kang-Mo Kim, Tae-Yong Ha, Sung-Hwa Kang, Nayoung Kim
    Digestive Surgery.2014; 31(4-5): 359.     CrossRef
  • Liver disease and malnutrition
    Tugrul Purnak, Yusuf Yilmaz
    Best Practice & Research Clinical Gastroenterology.2013; 27(4): 619.     CrossRef
  • A rapidly progressive and fatal case of nonalcoholic steatohepatitis following pancreaticoduodenectomy
    Hideaki Miura, Masayoshi Ijichi, Yoshitaka Ando, Korenobu Hayama, Kuniko IIhara, Haruki Yamada, Yasutsugu Bandai
    Clinical Journal of Gastroenterology.2013; 6(6): 470.     CrossRef
  • 11,549 View
  • 94 Download
  • Crossref